[Combination effect of pazufloxacin and anti-mrsa drugs against beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)].
The in vitro combination effects of pazufloxacin (PZFX) with an anti-MRSA drug such as vancomycin (VCM), teicoplanin (TEIC), arbekacin (ABK), minocycline (MINO), rifampicin (RFP) and sulfamethoxazole-trimethoprim (ST) were investigated against 26 strains of beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR) by the checkerboard method. The additive and synergistic effects were observed with the combination of PZFX and VCM (50%, 13/26 strains), PZFX and TEIC (96%, 25/26 strains), PZFX and ABK (65%, 17/26 strains), PZFX and MINO (46%, 12/26 strains), PZFX and ST (54%, 14/26 strains). The synergistic effects were observed with the combination of PZFX and TEIC (4%, 1/26 strains), PZFX and ABK or MINO (15%, 4/26 strains). The antagonistic effects were observed with only PZFX and MINO (12%, 3/26 strains), others were all indifference.
Yanagisawa
Chie
C
Kitasato Research Center for Anti-infection Drugs, The Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo, Japan.
Hanaki
Hideaki
H
Oishi
Tomohiro
T
Uehara
Kazuaki
K
Yamaguchi
Yukie
Y
Matui
Hidehito
H
Sunakawa
Keisuke
K
D000617:Aminoglycosides / Q000494:pharmacology; D003982:Dibekacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D024841:Fluoroquinolones / Q000494:pharmacology*; D066298:In Vitro Techniques; D016106:Methicillin Resistance; D008911:Minocycline / Q000494:pharmacology; D010078:Oxazines / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects*; D017334:Teicoplanin / Q000494:pharmacology; D020713:Vancomycin Resistance; D047090:beta-Lactams / Q000494:pharmacology
D000617:Aminoglycosides; D024841:Fluoroquinolones; D010078:Oxazines; D047090:beta-Lactams; D003982:Dibekacin; C078052:pazufloxacin; D017334:Teicoplanin; D008911:Minocycline; C031986:arbekacin